Source:http://linkedlifedata.com/resource/pubmed/id/15721840
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2005-2-21
|
pubmed:abstractText |
Interleukin 6 (IL-6) performs a prominent role during sepsis. To examine the molecular regulation of IL-6, IL-6 receptor, and signaling receptor gp130 during endotoxemia, nine healthy young volunteers received a bolus injection of lipopolysaccharide (LPS) on day 1 and saline on day 2 in a double blind, randomized, placebo-controlled trial. LPS enhanced IL-6 release 300-fold. IL-6 mRNA expression was not significantly altered in blood samples at any time after LPS infusion in vivo, while incubation of whole blood with 50 pg/ml LPS up-regulated IL-6 mRNA levels 8000- to 50,000-fold in vitro. LPS infusion increased synthesis of gp130 mRNA 5.5-fold compared to baseline at 4 h (P < 0.05), while no significant change was observed in the placebo period (P = 0.001 between groups). LPS increased the percentage of gp130 positive neutrophils gp130 700% over baseline at 8 h (P < 0.01 versus baseline and placebo). IL-6 receptor levels were not significantly altered by low-grade endotoxemia. In conclusion, endotoxemia up-regulates gp130 expression in vivo and in vitro. Quantification of IL-6 mRNA expression in circulating leukocytes is unlikely a suitable marker for monitoring of endotoxemia.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Cytokine Receptor gp130,
http://linkedlifedata.com/resource/pubmed/chemical/IL6ST protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Lipopolysaccharides,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-6
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1521-6616
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
114
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
293-8
|
pubmed:dateRevised |
2005-11-17
|
pubmed:meshHeading |
pubmed-meshheading:15721840-Adult,
pubmed-meshheading:15721840-Antigens, CD,
pubmed-meshheading:15721840-Cell Count,
pubmed-meshheading:15721840-Cytokine Receptor gp130,
pubmed-meshheading:15721840-Endotoxemia,
pubmed-meshheading:15721840-Humans,
pubmed-meshheading:15721840-Interleukin-6,
pubmed-meshheading:15721840-Leukocytes,
pubmed-meshheading:15721840-Lipopolysaccharides,
pubmed-meshheading:15721840-Male,
pubmed-meshheading:15721840-Membrane Glycoproteins,
pubmed-meshheading:15721840-Monocytes,
pubmed-meshheading:15721840-Neutrophils,
pubmed-meshheading:15721840-RNA, Messenger,
pubmed-meshheading:15721840-Receptors, Interleukin-6,
pubmed-meshheading:15721840-Time Factors
|
pubmed:year |
2005
|
pubmed:articleTitle |
Endotoxemia enhances expression of the signaling receptor (GP130) on protein and molecular level.
|
pubmed:affiliation |
Department of Clinical Pharmacology, Division of Hematology and Immunology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Wien, Austria, Europe.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|